Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy (Q38988662)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

object named as

Dario Neri

4

0 references

author name string

Francesca Pretto

1

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Nadia Castioni

3

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

publication date

4 June 2014

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Cancer Immunology, Immunotherapy

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

63

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

901-910

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1562-7

21 January 2018

Adverse consequences of immunostimulation

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1562-7

21 January 2018

Guidelines for the safe administration of high-dose interleukin-2.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1562-7

21 January 2018

Antibody-cytokine fusion proteins

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1562-7

21 January 2018

Immunocytokines: a novel class of potent armed antibodies

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1562-7

21 January 2018

Medical applications of single-chain antibodies

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1562-7

21 January 2018

"Diabodies": small bivalent and bispecific antibody fragments

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1562-7

21 January 2018

An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1562-7

21 January 2018

Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): results of a phase I trial in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1562-7

21 January 2018

Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1562-7

21 January 2018

Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1562-7

21 January 2018

A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1562-7

21 January 2018

Paclitaxel enhances therapeutic efficacy of the F8-IL2 immunocytokine to EDA-fibronectin-positive metastatic human melanoma xenografts

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1562-7

21 January 2018

Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1562-7

21 January 2018

The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1562-7

21 January 2018

Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1562-7

21 January 2018

A comparative immunofluorescence analysis of three clinical-stage antibodies in head and neck cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1562-7

21 January 2018

The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1562-7

21 January 2018

A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1562-7

21 January 2018

Phase I/II study of the tumour-targeting human monoclonal antibody-cytokine fusion protein L19-TNF in patients with advanced solid tumours

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1562-7

21 January 2018

High response rate after intratumoral treatment with interleukin-2

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1562-7

21 January 2018

The immunocytokine F8-IL2 improves the therapeutic performance of sunitinib in a mouse model of renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1562-7

21 January 2018

The antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1562-7

21 January 2018

The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1562-7

21 January 2018

Selective targeted delivery of TNFalpha to tumor blood vessels.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1562-7

21 January 2018

Pharmacotherapy of metastatic melanoma: emerging trends and opportunities for a cure

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1562-7

21 January 2018

Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1562-7

21 January 2018

Phase 0 microdosing PET study using the human mini antibody F16SIP in head and neck cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1562-7

21 January 2018

Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1562-7

21 January 2018

Different patterns of fibronectin and tenascin-C splice variants expression in primary and metastatic melanoma lesions.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1562-7

21 January 2018

Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1562-7

21 January 2018

The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1562-7

21 January 2018

Local and intralesional therapy of in-transit melanoma metastases

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1562-7

21 January 2018

Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1562-7

21 January 2018

Functional T Cells Targeting NY-ESO-1 or Melan-A Are Predictive for Survival of Patients With Distant Melanoma Metastasis

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1562-7

21 January 2018

Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1562-7

21 January 2018

Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1562-7

21 January 2018

Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1562-7

21 January 2018

The antibody-mediated targeted delivery of interleukin-10 inhibits endometriosis in a syngeneic mouse model

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1562-7

21 January 2018

The Antibody-Mediated Targeted Delivery of Interleukin-15 and GM-CSF to the Tumor Neovasculature Inhibits Tumor Growth and Metastasis

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1562-7

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1562-7

21 January 2018

Identifiers

10.1007/S00262-014-1562-7

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38988662&oldid=2202426765"